Abstract
Brain metastases are the most frequent neurological complication of cancer and the most common brain tumour type. Lung and breast cancers, and melanoma are responsible for up to three-quarters of metastatic brain lesions. Most patients exhibit either headache, seizures, focal deficits, cognitive or gait disorders, which severely impair the quality of life. Brain metastases are best demonstrated by MRI, which is sensitive but non-specific. The main differential diagnosis includes primary tumours, abscesses, vascular and inflammatory lesions. Overall prognosis is poor and depends on age, extent and activity of the systemic disease, number of brain metastases and performance status. In about half of the patients, especially those with widespread and uncontrolled systemic malignancy, death is heavily related to extra-neural lesions, and treatment of cerebral disease doesn't significantly improve survival. In such patients the aim is to improve or stabilize the neurological deficit and maintain quality of life. Corticosteroids and whole-brain radiotherapy usually fulfill this purpose. By contrast, patients with limited number of brain metastases, good performance status and controlled or limited systemic disease, may benefit from ag...Continue Reading
Citations
Jan 7, 2016·Journal of Medical Economics·A GuérinA R Macalalad
Apr 15, 2016·Clinical and Translational Imaging : Reviews in Nuclear Medicine and Molecular Imaging·Federico RoncaroliFederico E Turkheimer
Sep 14, 2016·Oncoimmunology·S Harrison FarberPeter E Fecci
Mar 24, 2016·BioMed Research International·Mao-hua ZhengKe-hu Yang
May 18, 2017·World Neurosurgery·Adela WuKaisorn L Chaichana
Sep 18, 2017·Clinical & Experimental Metastasis·Joo Yeon Nam, Barbara J O'Brien
Feb 12, 2015·Clinical Pharmacology and Therapeutics·K E ParrishW F Elmquist
Sep 12, 2015·The Journal of Pharmacology and Experimental Therapeutics·Karen E ParrishWilliam F Elmquist
Nov 6, 2018·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Sophia ScharlStephanie E Combs
Oct 20, 2018·Frontiers in Oncology·Maximilian J SchwendnerStephanie E Combs
Oct 4, 2014·PloS One·Linfeng ZhengGuixiang Zhang
Nov 26, 2015·The Journal of Pharmacology and Experimental Therapeutics·Shruthi VaidhyanathanWilliam F Elmquist
Jan 18, 2019·Medicine·Xiaoqing Yu, Yun Fan
Jul 5, 2019·Targeted Oncology·Changhui LiXueyan Zhang
Jan 24, 2020·Journal of Neuro-oncology·Jim ZhongHui-Kuo G Shu
May 27, 2017·Current Pharmacology Reports·Gautham GampaWilliam F Elmquist
Dec 12, 2018·Frontiers in Cellular Neuroscience·Ciro De LucaMichele Papa
Oct 18, 2020·International Journal of Molecular Sciences·Elizabeth Qian Xu MulcahyRoger Abounader
May 10, 2021·Colloids and Surfaces. B, Biointerfaces·Csilla FazakasAttila G Végh
Jul 18, 2021·Der Radiologe·Jan P BoströmIrenä Us A Adamietz
Jul 16, 2021·BMJ : British Medical Journal·Chris McKinnonPuneet Plaha
Jul 22, 2021·Thoracic Cancer·Donghui HouShijun Zhao
Apr 24, 2015·ACS Nano·Rameshwar PatilJulia Y Ljubimova
Aug 20, 2021·Advances in Radiation Oncology·Anthony C CasperJaden D Evans
Nov 3, 2021·Archives of Toxicology·Ana Dias-CarvalhoVera Marisa Costa